SCA
BMRN icon

SAC Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

SAC Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-62,853
Closed -$4.29M – 152
2014
Q1 		$4.29M Sell
62,853
-295,448
-82% -$21.8M 0.02% 595
2013
Q4 		$25.2M Buy
358,301
+231,962
+184% +$15.8M 0.15% 175
2013
Q3 		$9.12M Buy
126,339
+13,441
+12% +$893K 0.05% 410
2013
Q2 		$6.3M Buy
+112,898
New +$7.04M 0.03% 478

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's BMRN Position: Q2 2014 in Review

SAC Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 62,853 shares — an estimated $4.29M sold.

SAC Capital Advisors first reported a position in BMRN in Q2 2013 and held it in 4 quarters. The position peaked at $25.2M in Q4 2013. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • SAC Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 62,853 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $4.29M.
  • SAC Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's BioMarin Pharmaceuticals position peaked at $25.2M in Q4 2013.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.